Dive technology consist in a dopaminergic stimulation by continuous intra-cerebro ventricular delivery of anaerobic dopamine, in the third ventricle, closed to the target of the nigro-striatal system in Parkinson's disease at the stage of motor fluctuations:
The preclinical data displayed a huge symptomatic effect in MPTP mouse and 6 OH rat models without dyskinesia and a large therapeutic index as compared with
peripheral administration of L-dopa.
A neuroprotection of the dopaminergic neurons has been obtained within the substantia nigra and the striatum in the MPTP mouse model
- It is a powerful treatment of L-dopa related motor and non-motor complications with greater ergonomy (pump inside the body refilled every 3 months) and
efficacy than Duodopa® and apomorphine pump and lower surgical risk (easy surgery procedure without the risk of deep haemorrhage) and larger scope of
indications than deep brain stimulation (no post surgery dopamine depletion).
- It can be indicated at the end of the honeymoon period of the patients, if we consider the neuroprotection and neurorestoration properties and the finetuning of the adapted dose for each patient, which avoids degeneration worsening associated with under and over dosages.